Climb Bio

Ticker CLYM

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

11-50 Employees
Based in Wilmington, Delaware

Climb Bio is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. Their lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.

REPORT RATINGS

4.0 / 5.0 (1)

Climb Bio reports have an aggregate usefulness score of 4.0 based on 1 reviews.

Climb Bio